In this setting, IL-2WTFc again provided the largest reduction in tumour growth and was the only treatment to significantly improve survival compared to anti-TRP-1 monotherapy (Gehan–Breslow–Wilcoxon test, P=0.0446). The gene discussed is TYRP1; the disease is neoplasm.